» Articles » PMID: 24998974

Structure-dependent Binding and Activation of Perfluorinated Compounds on Human Peroxisome Proliferator-activated Receptor γ

Overview
Specialties Pharmacology
Toxicology
Date 2014 Jul 8
PMID 24998974
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Perfluorinated compounds (PFCs) have been shown to disrupt lipid metabolism and even induce cancer in rodents through activation of peroxisome proliferator-activated receptors (PPARs). Lines of evidence showed that PPARα was activated by PFCs. However, the information on the binding interactions between PPARγ and PFCs and subsequent alteration of PPARγ activity is still limited and sometimes inconsistent. In the present study, in vitro binding of 16 PFCs to human PPARγ ligand binding domain (hPPARγ-LBD) and their activity on the receptor in cells were investigated. The results showed that the binding affinity was strongly dependent on their carbon number and functional group. For the eleven perfluorinated carboxylic acids (PFCAs), the binding affinity increased with their carbon number from 4 to 11, and then decreased slightly. The binding affinity of the three perfluorinated sulfonic acids (PFSAs) was stronger than their PFCA counterparts. No binding was detected for the two fluorotelomer alcohols (FTOHs). Circular dichroim spectroscopy showed that PFC binding induced distinctive structural change of the receptor. In dual luciferase reporter assays using transiently transfected Hep G2 cells, PFCs acted as hPPARγ agonists, and their potency correlated with their binding affinity with hPPARγ-LBD. Molecular docking showed that PFCs with different chain length bind with the receptor in different geometry, which may contribute to their differences in binding affinity and transcriptional activity.

Citing Articles

Perfluorinated compounds linked to central precocious puberty in girls during COVID-19: an untargeted metabolomics study.

Li H, Xie M, Luo H, Cai Y, Liu L, Li H Front Endocrinol (Lausanne). 2025; 15():1491411.

PMID: 39777221 PMC: 11703715. DOI: 10.3389/fendo.2024.1491411.


Exposure to Per- and Polyfluoroalkyl Substances and Risk of Psoriasis: A Population-Based Study.

Zhang Q, Zhang M, Zhao C Toxics. 2024; 12(11).

PMID: 39591006 PMC: 11598214. DOI: 10.3390/toxics12110828.


Sex and obesity influence the relationship between perfluoroalkyl substances and lean body mass: NHANES 2011-2018.

Jia X, Liu W, Ling X, Li J, Ji J, Wang B Heliyon. 2024; 10(17):e35888.

PMID: 39319151 PMC: 11419868. DOI: 10.1016/j.heliyon.2024.e35888.


In vitro screening of understudied PFAS with a focus on lipid metabolism disruption.

Kashobwe L, Sadrabadi F, Braeuning A, Leonards P, Buhrke T, Hamers T Arch Toxicol. 2024; 98(10):3381-3395.

PMID: 38953992 PMC: 11402862. DOI: 10.1007/s00204-024-03814-2.


Risk-based prioritization of PFAS using phenotypic and transcriptomic data from human induced pluripotent stem cell-derived hepatocytes and cardiomyocytes.

Tsai H, Ford L, Chen Z, Dickey A, Wright F, Rusyn I ALTEX. 2024; 41(3):363-381.

PMID: 38429992 PMC: 11305846. DOI: 10.14573/altex.2311031.